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Prognostic nomogram for bladder cancer 
with brain metastases: a National Cancer 
Database analysis
Zhixian Yao1† , Zhong Zheng1†, Wu Ke1, Renjie Wang1, Xingyu Mu1, Feng Sun1, Xiang Wang1, Shivank Garg2, 
Wenyin Shi2*, Yinyan He3* and Zhihong Liu1*
Abstract 
Background: This study aimed to establish and validate a nomogram for predicting brain metastasis in patients with 
bladder cancer (BCa) and assess various treatment modalities using a primary cohort comprising 234 patients with 
clinicopathologically-confirmed BCa from 2004 to 2015 in the National Cancer Database.
Methods: Machine learning method and Cox model were used for nomogram construction. For BCa patients with 
brain metastasis, surgery of the primary site, chemotherapy, radiation therapy, palliative care, brain confinement of 
metastatic sites, and the Charlson/Deyo Score were predictive features identified for building the nomogram.
Results: For the original 169 patients considered in the model, the areas under the receiver operating characteristic 
curve (AUC) were 0.823 (95% CI 0.758–0.889, P < 0.001) and 0.854 (95% CI 0.785–0.924, P < 0.001) for 0.5- and 1-year 
overall survival respectively. In the validation cohort, the nomogram displayed similar AUCs of 0.838 (95% CI 0.738–
0.937, P < 0.001) and 0.809 (95% CI 0.680–0.939, P < 0.001), respectively. The high and low risk groups had median 
survivals of 1.91 and 5.09 months for the training cohort and 1.68 and 8.05 months for the validation set, respectively 
(both P < 0.0001).
Conclusions: Our prognostic nomogram provides a useful tool for overall survival prediction as well as assessing the 
risk and optimal treatment for BCa patients with brain metastasis.
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Background
As the top ranked malignancy of the urinary system, blad-
der cancer (BCa) incidence data in the US shows an esti-
mated 79,030 (8th among all sites) new cases and 16,870 
(8th among all sites) deaths in 2017 [1]. Unfortunately, 
10–15% of BCa patients already have metastasis at ini-
tial diagnosis and 15–30% high-grade BCa will eventually 
progress to advanced disease and lead to poor prognosis 
[2].
Despite an initial response to chemotherapy, patients 
with non-organ-confined disease fail to attain satisfac-
tory survival [3]. Since no optimally effective chemo-
therapeutic modality has been found, patients with NOC 
disease can barely survive for more than 3–6 months [4]. 
According to a previous population-based study of the 
SEER database, only 4.1% (76/1862) BCa patients had 
brain metastases in a cohort of 1862 patients with met-
astatic sites [5]. Given the rarity of brain metastases at 
presentation, currently, there is no randomized phase II 
or III clinical trials exploring outcomes of this group. The 
survival prognosis of this subgroup calls for significant 
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melioration when compared to those with cerebral 
metastasis from other malignancies [6].
Some reports have claimed that stereotactic radiosur-
gery and whole-brain irradiation can be a useful alterna-
tive approach for patients with brain metastasis in certain 
malignancies [7, 8]; however, suitable treatment for BCa 
patients with brain metastases remains unclear. A study 
conducted in 2002 in Cleveland retrospectively analyzed 
16 BCa patients with brain metastases and suggested 
more aggressive treatment rather than radiation therapy 
alone [9]. However, the cohort was too small to extract 
robust clinical traits. In 2010, Fokas et al. found no signif-
icant difference in survival after comparing radiotherapy 
alone with radiotherapy plus surgery in 62 patients with 
brain metastases from BCa [10]. Therefore, reconsidera-
tion of current medical strategies is indispensable, since 
the role of surgeries of the primary tumor or radiother-
apy of brain lesions in the treatment of metastatic BCa is 
still obscure.
Although previous studies have identified several 
prognostic factors of poor outcome in advanced BCa, 
such as the presence of visceral metastasis, anemia, and 
C-reactive protein (CRP) [3, 11, 12], it remains unknown 
whether they could be applied to the clinical assessment. 
Currently, prognostic nomograms are widely applied as 
prognostic devices in oncologic medicine. With the abil-
ity to incorporate clinical characteristics to generate indi-
vidual probabilities of clinical events, nomograms can aid 
clinical decisions and facilitate our drive towards per-
sonalized medicine [13]. The purpose of our study was 
to create a nomogram predicting overall survival (OS) of 
BCa patients with brain metastasis and evaluate suitable 
therapeutic modalities for this cohort.
Materials and methods
Study population
The National Cancer Database (NCDB) was queried for 
patients initially diagnosed with histological confirmed 
BCa (topographical code C67, International Classifica-
tion of Diseases for Oncology, 3rd edition) between 2004 
and 2015. Patients with brain metastatic disease at the 
time of presentation were selected for the analysis.
Baseline medical traits (including age; sex, race; path-
ological grade; tumor histology, lymph node vascular 
invasion, and clinical stage [TNM] of the American Joint 
Committee on Cancer; surgical statuses of the primary 
and metastatic sites; chemotherapy; radiation therapy; 
and palliative care) were derived from medical records 
(Table  1). Other inclusion criteria were as follows: 
age > 18 years; BCa as the primary cancer diagnosis; brain 
metastasis; other distant metastatic sites including bone, 
liver, lung, and distant lymph node involvement; active 
follow-up; and patients with > 30 days of survival. Patients 
without sufficient information about distant metastatic 
sites or survival data were excluded. No detailed data 
were available regarding the specific types of chemother-
apy or hormonal therapy or palliative care agents. Finally, 
we included 234 patients with the above-mentioned cri-
teria. We used a computer-generated random seed to 
assign 169 of these patients to the training set, and 65 
patients to the internal testing set for subsequent analy-
sis. Work of flow is displayed in Fig. 1.
Compliance with ethical standards
The NCDB is a hospital-based registry of cases treated 
at American College of Surgeons Commission on Can-
cer accredited cancer programs. Extraction of data from 
the NCDB did not require extra informed consent. All 
the data were downloaded at the Sidney Kimmel Cancer 
Center of Thomas Jefferson University.
Statistical analysis
For feature selection, we used the least absolute shrink-
age and selection operator (LASSO) method, which is a 
machine learning method suitable for the reduction of 
high-dimensional data [14]. Eighteen variables were used 
to select the most useful predictive features from the pri-
mary data set. The LASSO regression model analysis was 
performed using the glmnet package of R (R Foundation 
for Statistical Computing, Vienna, Austria).
Univariate and multivariate Cox regression analysis 
were performed to explore the independent prognos-
tic factors via the survival package of R. The Schoenfeld 
residuals method was applied to test the proportional 
hazards assumption for the Cox regression model fit. 
Each regression coefficient of selected variables was 
converted to a 0 to 100 scale proportion according to its 
contribution. These points were added across enrolled 
variables to generate total points, which were then trans-
formed to predicted probabilities. For clinical use, the 
predictive performance of the nomogram was measured 
via time-dependent receiver operating characteristic 
(ROC) analysis with area under the curve (AUC) values. 
Calibration was employed with bootstrapping to decrease 
the bias of over-fitting. The x-axis represented the pre-
diction calculated using the nomogram, and the y-axis 
the actual risk odds for the individual. The 45-degree 
line represented an ideal performance of the nomogram, 
in which the predicted outcome perfectly corresponded 
with the actual outcome. The model that incorporated 
the above independent predictors was developed and 
presented as the nomogram. Nomogram and calibra-
tion plots were obtained using the rms and nomogramEx 
packages of R.
Survival analysis was performed using the Kaplan–
Meier method to probe the correlation between variables 
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and OS, and the log-rank test was performed to com-
pare survival variance in different groups. Decision curve 
analysis were performed to compare with the current 
AJCC TNM staging system. All statistical tests and analy-
ses were performed in R software version 3.5.1. Statistical 
significance was set at < 0.05.
Results
Clinicopathologic characteristics
During the study procedure, 268 consecutive BCa 
patients with brain-involvement were identified from 
the NCDB. Of these, 234 patients with brain metastasis 
in accordance with the inclusion criteria were enrolled, 
and 169 and 65 patients were randomly divided into the 
training and internal validation cohorts, respectively. The 
clinicopathologic characteristics and baseline data in the 
primary and validation cohorts are provided in Table 2. 
The median follow-up time was 3.38 (range: 1.08–61.21) 
months.
Feature selection via LASSO
LASSO with tenfold cross-validation generated 7 vari-
ables out of 18 features: Grade, Surgery_Primary, 
Chemotherapy, Radiation_Therapy, Paliative_Care, 
Table 1 Description of clinical characteristics and their values
Clinical variables Description Values
Age Age of the patient at diagnosis < 65 years or ≥ 65 years
Sex The gender of the patient Male or female
Race The primary race of the person White, black or others
Grade Describes the tumor’s resemblance to normal tissue (coded 
according to ICD-O-3)
Well differentiated, poorly differentiated or Unknown
Tumor_Stage NCDB analytic stage identifies the clinically or pathologically 
determined size and/or extension of the primary tumor (cT) 
as defined by the American Joint Committee on Cancer 
(AJCC)
High (Stage III, IV) or low (Stage I, II)
Lymph_nodes Identifies the clinically-determined absence or presence of 
regional lymph node metastasis and describes the corre-
sponding extent as defined by the American Joint Commit-
tee on Cancer (AJCC)
Yes, no or unknown
Histology Indicate the pathological histology of tumor cells (coded 
according to ICD-O-3)
Transitional cell carcinoma, papillary urothelial carcinoma, small 
cell carcinoma or others
Lymph_Vas_invasion Indicate the presence or absence of tumor cells in lymphatic 
channels (other than lymph nodes) or blood vessels within 
the primary tumor as noted microscopically by the patholo-
gist
Yes, no or unknown
Met_Bone Indicate the presence of distant involvement of bone at the 
time of diagnosis
Yes or no
Met_Liver Indicate the presence of distant involvement of liver at the 
time of diagnosis
Yes or no
Met_Lung Indicate the presence of distant involvement of lung at the 
time of diagnosis
Yes or no
Surgery_Primary Records the surgical procedure and approach performed to 
the primary site
Minimal invasive surgery, non-minimal invasive surgery or no 
surgery
Chemotherapy Records of chemotherapy administrated as first course treat-
ment
Yes or no
Radiation_Therapy Anatomic target volume is directed at tumors lying within the 
substance of brain or its meninges
Yes or no
Paliative_Care Any care provided an effort to palliate or alleviate symptoms Yes or no
Brain_Confined_Met Indicate the presence of distant involvement of brain only or 
brian combined with other organs at the time of diagnosis
Brain confined or non-brain confined
CDCC_Score Charlson/Deyo Score, a weighted score derived from the 
sum of the scores for each of the comorbid conditions 
listed in the Charlson Comorbidity Score Mapping Table 
(source http://dx.doi.org/10.17632 /nn6y5 8v8vv .1#file-a7273 
5e9-15b5-4a10-aef5-dedda d2463 e8)
0–3
Surgery_Met Records the surgical removal of distant lymph nodes or other 
tissues or organs beyond the primary site
Yes or no
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Brain_Confined_Met, and CDCC_Score (Fig. 2a, b). The 
results of the univariate and multivariate Cox regres-
sion of the primary cohort are recorded in Table  3. 
Surgery_Primary, Chemotherapy, Radiation_Therapy, 
Paliative_Care, Brain_Confined_Met, and CDCC_Score 
were chosen for further analysis (apart from Radia-
tion_Therapy, all other variables were independent prog-
nostic factors in the LASSO Cox model; the reason for 
including this variable will be explained in “Discussion”)
P values for Schoenfeld residuals method were all > 0.05 
which fitted the proportional hazards assumption for the 
Cox model (Additional file 1: Fig. S1).
Development and validation of the prognostic nomogram
The prognostic nomogram that integrated all selected 
factors for OS in the primary cohort is shown in Fig. 3. 
We then derived a formula to calculate the risk score 
for odds of death for every patient based on their indi-
vidual status of the selected variables above. To take one 
patient for example (purple track in Fig. 3), basing on the 
selected features, the total points adds up to 323 and thus 
the corresponding 0.5- and 1-year death probabilities 
are 0.647 and 0.9 respectively. The equation of each vari-
able and computational formula is presented in Table 4. 
We further stratified those patients with an average or 
higher-than-average risk score into the high risk group 
and those with lower-than-average risk score into the low 
risk group (Table  1). In terms of 0.5- and 1-year OS of 
the training set, our six-clinical variable-based classifier 
demonstrated favorable discrimination with AUC val-
ues of 0.823 (95% confidence interval [CI] 0.758–0.889, 
P < 0.001) and 0.854 (95% CI 0.785–0.924, P < 0.001), 
respectively (Fig. 4a). The internal-bootstrapped calibra-
tion plot for the probability of survival at 0.5 or 1  year 
Fig. 1 Flowchart of the analysis
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Table 2 Baseline characteristics and distribution of risk stratification of patients in the training and validation cohorts
Characteristics Training set (%) Internal testing set (%)
Number of cases High risk Low risk Number of cases High risk Low risk
Age
 < 65 years 71 (42) 32 (18.9) 39 (23.1) 22 (33.8) 11 (16.9) 11 (16.9)
 ≥ 65 years 98 (58) 49 (29) 49 (29) 43 (66.2) 21 (32.3) 22 (33.8)
Sex
 Male 128 (75.7) 63 (37.3) 65 (38.5) 47 (72.3) 19 (29.2) 28 (43.1)
 Female 41 (24.3) 18 (10.7) 23 (13.6) 18 (27.7) 13 (20) 5 (7.7)
Race
 White 148 (87.6) 70 (41.4) 78 (46.2) 59 (90.8) 29 (44.6) 30 (46.2)
 Black 16 (9.5) 8 (4.7) 8 (4.7) 4 (6.2) 3 (4.6) 1 (1.5)
 Others 5 (3) 3 (1.8) 2 (1.2) 2 (3.1) 0 (0) 2 (3.1)
Grade
 Well differentiated 14 (8.3) 10 (5.9) 4 (2.4) 1 (1.5) 0 (0) 1 (1.5)
 Poorly differentiated 96 (56.8) 39 (23.1) 57 (33.7) 39 (60) 19 (29.2) 20 (30.8)
 Unknown 59 (34.9) 32 (18.9) 27 (16) 25 (38.5) 13 (20) 12 (18.5)
Histology
 TCC 94 (55.6) 49 (29) 45 (26.6) 38 (58.5) 17 (26.2) 21 (32.3)
 PUC 42 (24.9) 15 (8.9) 27 (16) 8 (12.3) 5 (7.7) 3 (4.6)
 SCC 10 (5.9) 3 (1.8) 7 (4.1) 7 (10.8) 2 (3.1) 5 (7.7)
 Others 23 (13.6) 14 (8.3) 9 (5.3) 12 (18.5) 8 (12.3) 4 (6.2)
Tumor_Stage
 Low 13 (7.7) 7 (4.1) 6 (3.6) 4 (6.2) 2 (3.1) 2 (3.1)
 High 156 (92.3) 74 (43.8) 82 (48.5) 61 (93.8) 30 (46.2) 31 (47.7)
Lymph_nodes
 No 87 (51.5) 39 (23.1) 48 (28.4) 33 (50.8) 16 (24.6) 17 (26.2)
 Yes 36 (21.3) 14 (8.3) 22 (13) 17 (26.2) 9 (13.8) 8 (12.3)
 Unknown 46 (27.2) 28 (16.6) 18 (10.7) 15 (23.1) 7 (10.8) 8 (12.3)
Lymph_Vas_Invasion
 No 31 (18.3) 12 (7.1) 19 (11.2) 12 (18.5) 5 (7.7) 7 (10.8)
 Yes 29 (17.2) 13 (7.7) 16 (9.5) 6 (9.2) 3 (4.6) 3 (4.6)
 Unknown 109 (64.5) 56 (33.1) 53 (31.4) 47 (72.3) 24 (36.9) 23 (35.4)
Met_Bone
 No 112 (66.3) 47 (27.8) 65 (38.5) 44 (67.7) 26 (40) 18 (27.7)
 Yes 57 (33.7) 34 (20.1) 23 (13.6) 21 (32.3) 6 (9.2) 15 (23.1)
Met_Liver
 No 129 (76.3) 61 (36.1) 68 (40.2) 50 (76.9) 25 (38.5) 25 (38.5)
 Yes 40 (23.7) 20 (11.8) 20 (11.8) 15 (23.1) 7 (10.8) 8 (12.3)
Met_Lung
 No 100 (59.2) 40 (23.7) 60 (35.5) 34 (52.3) 16 (24.6) 18 (27.7)
 Yes 69 (40.8) 41 (24.3) 28 (16.6) 31 (47.7) 16 (24.6) 15 (23.1)
Surgery_Primary
 Minimal invasive 65 (38.5) 27 (16) 38 (22.5) 31 (47.7) 19 (29.2) 12 (18.5)
 No 83 (49.1) 48 (28.4) 35 (20.7) 29 (44.6) 9 (13.8) 20 (30.8)
 Non-minimal invasive 21 (12.4) 6 (3.6) 15 (8.9) 5 (7.7) 4 (6.2) 1 (1.5)
Chemotherapy
 No 97 (57.4) 77 (45.6) 20 (11.8) 36 (55.4) 28 (43.1) 8 (12.3)
 Yes 72 (42.6) 4 (2.4) 68 (40.2) 29 (44.6) 4 (6.2) 25 (38.5)
Radiation_Therapy
 No 89 (52.7) 50 (29.6) 39 (23.1) 38 (58.5) 14 (21.5) 24 (36.9)
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after surgery showed an optimal agreement between pre-
diction by nomogram and actual observation (Fig. 4b, c). 
In the validation cohort, the nomogram displayed similar 
AUC values of 0.838 (95% CI 0.738–0.937, P < 0.001) and 
0.809 (95% CI 0.680–0.939, P < 0.001) for the estimation 
of survival (Fig. 4d). There was also a well-behaved cali-
bration curve for the survival estimation (Fig. 4e, f ).  
Kaplan–Meier survival analysis yielded a significant 
difference in survival between the training cohort and 
validation set. The median survival of the High and Low 
risk groups were 1.91 and 5.09  months in the training 
cohort (Fig. 5a) and 1.68 and 8.05 months in the valida-
tion set (Fig. 5b), respectively (both P < 0.0001).
TCC transitional cell carcinoma, PUC papillary urothelial carcinoma, SCC small cell carcinoma
Table 2 (continued)
Characteristics Training set (%) Internal testing set (%)
Number of cases High risk Low risk Number of cases High risk Low risk
 Yes 80 (47.3) 31 (18.3) 49 (29) 27 (41.5) 18 (27.7) 9 (13.8)
Palliative_Care
 No 122 (72.2) 62 (36.7) 60 (35.5) 47 (72.3) 21 (32.3) 26 (40)
 Yes 47 (27.8) 19 (11.2) 28 (16.6) 18 (27.7) 11 (16.9) 7 (10.8)
Brain_Confined_Met
 No 67 (39.6) 24 (14.2) 43 (25.4) 22 (33.8) 13 (20) 9 (13.8)
 Yes 102 (60.4) 57 (33.7) 45 (26.6) 43 (66.2) 19 (29.2) 24 (36.9)
CDCC_Score
 0 116 (68.6) 50 (29.6) 66 (39.1) 46 (70.8) 23 (35.4) 23 (35.4)
 1 37 (21.9) 19 (11.2) 18 (10.7) 12 (18.5) 8 (12.3) 4 (6.2)
 2 10 (5.9) 7 (4.1) 3 (1.8) 5 (7.7) 1 (1.5) 4 (6.2)
 3 6 (3.6) 5 (3) 1 (0.6) 2 (3.1) 0 (0) 2 (3.1)
Surgery_Met
 No 144 (85.2) 72 (42.6) 72 (42.6) 55 (84.6) 25 (38.5) 30 (46.2)
 Yes 25 (14.8) 9 (5.3) 16 (9.5) 10 (15.4) 7 (10.8) 3 (4.6)
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Fig. 2 Clinical trait selection via the least absolute shrinkage and selection operator (LASSO) cox regression model. a Tenfold cross-validated error 
(first vertical line equals the minimum error (lambda = 0.066), whereas the second vertical line shows the cross-validated error within 1 standard 
error of the minimum). b The profile of coefficients in the model at varying levels of penalization plotted against the log (lambda) sequence
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Moreover, the decision curve analysis demonstrated 
that when the threshold probability was greater than 0.4, 
the nomogram presented more net benefit than TNM 
system in terms of OS prediction (Fig. 6).
Discussion
In this study, we developed and validated a novel prog-
nostic tool based on six clinical variables to improve the 
prediction of OS for patients with confirmed BCa with 
metastatic brain lesions. Our results showed that this 
tool can well categorize patients into high-risk and low-
risk groups with large differences in OS.
Generally, in our research, prognostic factors are 
closely related to the choices of treatment modalities, 
as well as the comorbidities and metastatic conditions 
of the patient. Known as the best method of determin-
ing comorbidity conditions, higher Charlson/Deyo Score 
(CDCC_Score) is reported as a poor prognostic factor for 
overall mortality and cancer-specific mortality in meta-
static BCa [15], consistent with our findings. In a previ-
ous study, multisite metastasis was found to be able to 
independently predict worse OS compared with single 
metastatic sites in BCa patients [5]. Our results are in line 
Table 3 Univariate and multivariate Cox regression analysis of BCa patients based on clinicopathological characteristics 
derived from NCDB data in the training cohort
Characteristics Univariate analysis HR 
(95% CI)
P value Multivariate analysis HR 
(95% CI)
P value
Age (< 65 years vs. ≥ 65 years) 1.117 (0.819–1.525) 0.48 1.032 (0.705–1.511) 0.87
Sex (male vs. female) 0.861 (0.602–1.233) 0.42 1.166 (0.756–1.797) 0.49
Race
 White vs. black 0.871 (0.509–1.489) 0.61 0.956 (0.523–1.747) 0.88
 White vs. others 0.889 (0.363–2.174) 0.80 0.524 (0.197–1.39) 0.19
Grade
 Well differentiated vs. poorly differentiated 0.896 (0.511–1.574) 0.70 1.317 (0.653–2.656) 0.44
 Well differentiated vs. unknown 1.144 (0.636–2.057) 0.65 1.634 (0.753–3.546) 0.21
Histology
 TCC vs. PUC 0.851 (0.588–1.232) 0.39 1.181 (0.738–1.89) 0.49
 TCC vs. SCC 1.083 (0.563–2.087) 0.81 1.495 (0.714–3.13) 0.29
 TCC vs. others 0.916 (0.578–1.45) 0.71 0.629 (0.363–1.09) 0.10
Lymph_nodes
 No vs. yes 0.835 (0.564–1.234) 0.37 0.808 (0.51–1.28) 0.36
 No vs. unknown 0.985 (0.682–1.422) 0.93 0.761 (0.485–1.196) 0.24
Lymph_Vas_Invasion
 No vs. yes 1.098 (0.658–1.832) 0.72 1.494 (0.816–2.736) 0.19
 No vs. unknown 1.291 (0.859–1.94) 0.22 1.269 (0.764–2.107) 0.36
Tumor_Stage (low vs. high) 1.247 (0.704–2.21) 0.45 1.089 (0.536–2.211) 0.81
Met_Bone (no vs. yes) 1.026 (0.742–1.42) 0.88 0.61 (0.374–0.997) 0.05
Met_Liver (no vs. yes) 0.978 (0.683–1.4) 0.90 1.223 (0.761–1.966) 0.41
Met_Lung (no vs. yes) 1.317 (0.962–1.802) 0.09 0.878 (0.525–1.469) 0.62
Surgery primary
 Minimal invasive surgery vs. no surgery 1.44 (1.031–2.011) 0.03 2.529 (1.609–3.975) < 0.001
 Minimal invasive surgery vs. non-minimal invasive 0.923 (0.558–1.525) 0.75 1.253 (0.672–2.334) 0.48
Chemotherapy (no vs. yes) 0.353 (0.25–0.498) < 0.001 0.213 (0.137–0.332) < 0.001
Radiation_Therapy (no vs. yes) 0.723 (0.53–0.986) 0.04 0.708 (0.486–1.031) 0.07
Palliative_Care (no vs. yes) 0.922 (0.651–1.305) 0.65 0.631 (0.413–0.964) 0.03
Brain_Confined_Met (non–brain confined vs. brain confined) 1.248 (0.911–1.71) 0.17 2.229 (1.144–4.345) 0.02
CDCC_Score
 0 vs. 1 1.29 (0.886–1.878) 0.18 1.439 (0.929–2.23) 0.10
 0 vs. 2 1.529 (0.798–2.926) 0.20 1.865 (0.861–4.038) 0.11
 0 vs. 3 2.14 (0.932–4.91) 0.07 2.545 (1.035–6.256) 0.04
Surgery_Met (yes vs. no) 0.9 (0.58–1.396) 0.64 0.918 (0.546–1.542) 0.75
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with the study above since brain-confined metastatic dis-
ease was related with better survival.
Treatment for the metastatic group is not beyond dis-
pute. Our study included 4 treatment variables: Surgery_
Primary, Surgery_Met, Chemotherapy, Paliative_Care 
and Radiation_Therapy.
A previous study indicated that surgical management 
of the primary BCa might contribute to long-term dis-
ease-free survival in selected patients [16]. Chen et  al. 
also suggested that surgical management of the primary 
BCa might improve OS outcomes among patients [17]. 
Our study uncovered that brain metastatic BCa patients 
can still benefit from surgical operation of the primary 
site via minimal invasive surgery or otherwise. As for 
surgeries of the metastatic site, limited conclusions could 
be drawn for the lack of unanimous reporting elements 
and resection of solitary lung metastasis may result in OS 
improvement when integrated with chemotherapy [18]. 
As shown in the nomogram, though resistance may easily 
show up, chemotherapy still exerts maximal survival ben-
efit for brain-metastatic BCa patients, which correlates 
to the first-line treatment of the European Association 
Fig. 3 Nomogram to estimate the risk and predict the survival of BCa patients with brain metastasis. Bars in blue display the distribution of patients 
in the training cohort. To calculate the total points of a specific patient, locate the value of each variable on the top point axis, add the points from 
all of the variables, and draw a vertical line from the total point axis to determine the 0.5 and 1 year death probabilities at the lower line of the 
nomogram. Purple track provided an example for the calculation of total-points-to-outcome (*P < 0.05, **P < 0.01, ***P < 0.001)
Table 4 The risk point of each variable and computational 
formula of OS
0.5-Year Survival = 7.5e−08 * points ^3 − 2.7837e−05 * points 
^2 − 0.001082565 * points + 0.815518912
1-Year survival = 1.21e−07 * points ^3 − 2.3544e−05 * points 
^2 − 0.003130703 * points + 0.651899934
Clinical variables Values Risk points
Radiation_Therapy No 56
Yes 42
Palliative_Care No 56
Yes 40
Brain_Confined_Met Non-brain confined 73
Brain confined 56
CDCC_Score 1 56
2 74
3 76
4 100
Surgery_Primary No 90
Minimal invasive 56
Non-minimal invasive 53
Chemotherapy No 56
Yes 0
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of Urology guidelines [19]. Given that more than half of 
patients with metastatic urothelial cancer are unfit for 
cisplatin-based chemotherapy, the choice of chemother-
apy combination will have to depend on the health condi-
tion of patients. Consensus from an international survey 
among urologic experts was reached to define patients 
unfit for cisplatin-based chemotherapy, which was as 
follows: performance score > 1, glomerular filtration 
rate ≤ 60  ml/min/1.73  m2, grade 2 audiometric loss and 
peripheral neuropathy, and New York Heart Association 
class III heart failure [20, 21]. Palliative care is defined 
as any procedures to alleviate symptoms distinguishable 
from the same modality used for curative intent, which 
may include surgery, radiation therapy, systemic therapy, 
and/or other pain management drugs. Advanced BCa 
can be associated with problems like ureteral obstruc-
tion, persistent bleeding, pain, and/or voiding com-
plaints; palliative care may prolong life expectancy in 
these patients [22]. The variable Radiation_Therapy was 
fitted into the analysis because although the P value 0.07 
slightly surpassed 0.05 in the multivariate Cox model, it 
was 0.04 in the univariate analysis. Moreover, for brain 
metastatic cancer, conventional fractionated whole brain 
radiotherapy is still frequently used as a standard therapy 
[23]; thus, we included it in the prognostic nomogram for 
clinical consideration.
To the best of our knowledge, this is the largest cohort 
study exploring the prognostic significance of BCa with 
brain metastasis and the effect of various treatments on 
patients’ prognoses; however, several limitations are still 
noteworthy. For example, information regarding metas-
tasectomy for specific metastatic sites was incomplete. In 
addition, there was a lack of details and sequences con-
cerning chemotherapy, endocrine therapy, immunologi-
cal treatment, and radiation therapy. As a retrospective 
study population from different medical facilities, some 
baseline characteristics may be non-uniform and external 
validation cohorts are needed to confirm the predictive 
accuracy of the nomogram.
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
1 Specificity
Se
ns
itiv
ity
AUC of 0.5 year survival:  0.838
AUC of 1 year survival:  0.809
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Nomogram–Predicted 
Probability of 0.5–Year Survival
Ac
tu
al
 0
.5
Ye
a
r 
Su
rv
iva
l
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Nomogram–Predicted 
Probability of 1–Year Survival
Ac
tu
al
 1
Ye
a
r 
Su
rv
iva
l
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
1–Specificity
Se
ns
itiv
ity
AUC of 0.5 year survival:  0.823
AUC of 1 year survival:  0.854
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Ac
tu
al
 0
.5
Ye
a
r 
Su
rv
iva
l
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Nomogram–Predicted 
Probability of 1–Year Survival
Ac
tu
al
 1
Ye
a
r 
Su
rv
iva
l
a b c
d e f
Nomogram Predicted 
Year SurvivalProbability of 0.5
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Conclusion
By combining six clinical factors of brain-metastatic BCa 
patients, we constructed a prognostic nomogram. The 
model provides an optimal estimation of OS and refer-
ence for suitable treatments in BCa patients with brain 
metastasis.
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